Northside Capital Management LLC Has $321,000 Stock Position in Novartis AG (NYSE:NVS)

Northside Capital Management LLC grew its holdings in Novartis AG (NYSE:NVS) by 29.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,296 shares of the company’s stock after purchasing an additional 750 shares during the period. Northside Capital Management LLC’s holdings in Novartis were worth $321,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Integral Health Asset Management LLC grew its position in Novartis by 33.3% in the second quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after purchasing an additional 75,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Novartis by 115.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after buying an additional 124,111 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Novartis by 343.5% in the 2nd quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock valued at $70,652,000 after acquiring an additional 509,567 shares in the last quarter. CWA Asset Management Group LLC boosted its position in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after purchasing an additional 5,164 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Novartis by 135.5% during the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVS has been the subject of several recent analyst reports. Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets boosted their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $121.50.

Novartis Trading Down 0.3 %

Shares of Novartis stock opened at $99.05 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The business has a fifty day simple moving average of $101.13 and a two-hundred day simple moving average of $109.19. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The company has a market capitalization of $202.46 billion, a price-to-earnings ratio of 11.50, a P/E/G ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the company posted $1.74 EPS. Research analysts forecast that Novartis AG will post 7.63 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.